Trim 50-70% of position at $28.80, retain partial exposure for recovery scenario

• $13.5 billion cumulative impairments across 2024-2025 with Q2 2026 write-down of $4.33 billion, signaling pattern of capital destruction rather than isolated event
• Tangible book value at negative $38.5 billion leaves minimal balance sheet cushion for future write-downs
• FCF coverage deteriorating sharply: 93% FY2025, 12.3% Q2 2026 alone, ~51% H1 2026; full-year 2026 could fall below 80% threshold where boards review payout policy
• Dividend yield of 6% is a risk warning signal, not a support level, given impairment pattern and patent cliff overhang
• Technical momentum divergence: RSI rolled from 77 to 63, MACD histogram flipped negative for first time since late July, stock rejected upper Bollinger Band at 29.42 and failed to hold 29.21 intraday high
• Fair value range of $16-$18 based on conservative normalized EPS of $2.10-$2.30 (vs $2.90 consensus) and 7-8x multiple during impaired credibility periods
• Higher-for-longer rates risk multiple compression rather than expansion, as 9.8x forward P/E already discounts pipeline optionality; beta of 0.30 protects against earnings misses but not structural repricing
• Pipeline catalysts (COMIRNATY XFG, ADC deal, berobenatide) carry execution risk against entrenched competitors (Lilly, Novo Nordisk) and recent 25% move from $23 to $29 already prices in optimism

→ vs aggressive: Normalized earnings of $14.8 billion assume no further impairments from Seagen re-evaluation; third significant write-down in two years suggests this is a base case, not a tail risk

→ vs aggressive: Dividend safety argument relying on liquidity is a snapshot, not a trend; FCF coverage at 12.3% in Q2 2026 and 51% in H1 2026 is sharp deterioration, not transition

→ vs aggressive: Technical golden cross and 25% one-year return confirm uptrend but do not indicate attractive risk-adjusted entry; overbought stock failing at resistance with momentum decay is high-risk zone

→ vs aggressive: Higher-for-longer rates thesis incomplete: if 10-year yield rises on Fed hike, present value of long-dated pipeline assets discounts lower, compressing multiple rather than expanding it

→ vs neutral: Defaulting to hold by defaulting to bullish read accepts asymmetric downside in exchange for upside requiring multiple pipeline catalysts to confirm; does not address FCF deterioration or impairment pattern

Partial trim of 25-40% with staged exits, hedging via put spreads/collars, and clear re-entry triggers rather than full hold or full exit

• The aggressive analyst's normalized earnings ($2.1B) treats model outputs as facts; $13.5B cumulative value destruction from capital allocation cannot be dismissed as noise
• 9.8x forward earnings embeds significant pessimism but Q1 2026 results confirm the underlying business is still functioning
• Dividend trajectory is real and the 6% yield reflects market pricing of that risk, not temporary mispricing
• Conservative analyst's $16-$18 fair value is a bear case, not a base case; assumes complete earnings recovery failure across multiple dimensions
• MACD histogram negative by 1 basis point after multi-week uptrend is momentum deceleration, not a reversal pattern; RSI 77 to 63 is a normal reset allowing bull markets to extend
• Exit target of $28.80 has already been passed by the market at $29.21; proposed stop at $25.82 (50 SMA) exits at the worst level if the trend tests that moving average
• Three to six months of $26-$30 range with elevated volatility is the most likely scenario, requiring partial positioning with active risk management rather than binary commitment
• Re-entry conditions should be specific: stock above $28.34 (10 EMA) for 3-5 sessions, MACD histogram positive, and Q3 2026 FCF coverage above 80% annualized

→ vs aggressive: Normalized earnings of $2.1B are model outputs, not facts; dismissing $13.5B of cumulative value destruction from capital allocation as 'noise' is not credible when the pattern spans five years and three major write-downs

→ vs conservative: The $16-$18 fair value is a bear case masquerading as a base case, assuming complete failure across Seagen integration, cost programs, and macro conditions simultaneously

→ vs conservative: The MACD histogram crossing zero by 1 basis point and RSI moving from 77 to 63 represent momentum normalization in an uptrend, not reversal signals

→ vs conservative: Exit at $28.80 is already behind the market (stock printed $29.21) and the stop at $25.82 aligns exactly with the 50 SMA, guaranteeing exit at the worst possible level during any meaningful pullback